According to the audit made by DSM Group analytical agency, Valenta’s Ingavirin® took the first position among antiviral medicines for flu in value terms of sales at the pharmaceutical outlets of Russia in January-April 2016. Sales of Ingavirin® grew 37% in comparison with the same period of 2015. In April, the medicine also took the leading positions in value terms of sales.
Besides, in January-April 2016, growth of retail sales in number of sold packages of Ingavirin® was registered. This parameter increased more than 1.4 times.